N4 Pharma PLC Grant of Options (2516N)
18 Mayo 2020 - 10:29AM
UK Regulatory
TIDMN4P
RNS Number : 2516N
N4 Pharma PLC
18 May 2020
18 May 2020
N4 Pharma plc
("N4 Pharma", the "Company" or the "Group")
Grant of Options
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for cancer treatments
and vaccines, announces the Company has today granted 1,434,286
options (the "Options") over ordinary shares of 0.4 pence in the
Company ("Ordinary Shares") to certain Directors of the Company.
These Options have been granted pursuant to the Company's
Unapproved Share Option Scheme, as follows:
Director Number of Options Existing options Total Options over
granted over Ordinary Ordinary Shares
Shares held held following grant
David Templeton
Executive Director 717,143 717,143 1,434,286
Luke Cairns
Non-Executive Director 717,143 1,392,445 2,109,588
The Options have an exercise price of 4.8 pence per Option,
being the closing mid-market price of an Ordinary Share on 15 May
2020, the business day prior to the grant. The Options can be
exercised from three years from the grant date and up to the tenth
anniversary of the grant date, provided that the individual remains
an employee of the Company. Following the grant of the Options, the
Company has options in issue over a total of 8,396,513 Ordinary
Shares, representing 8.28 per cent. of the Company's current issued
share capital, or 5.52 per cent. of the Company's issued share
capital as enlarged by the placing announced on 13 May 2020.
The FCA notifications, made in accordance with the requirements
of the EU Market Abuse Regulation, are appended below.
Enquiries:
N4 Pharma Plc Via Scott PR
Nigel Theobald, CEO
Allenby Capital Limited Tel: +44(0)203 328 5656
James Reeve/Asha Chotai
Scott PR Tel: +44(0)1477 539 539
Georgia Smith
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for cancer and vaccine treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for cancer and vaccine treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre clinical and clinical programs, N4
Pharma will seek to receive up front payments, milestone payments
and ultimately royalty payments once products reach the market.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name David Templeton
----------------------- ----------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------
a) Position/status Executive Director
----------------------- ----------------------------------------------
b) Initial notification Initial notification
/Amendment
----------------------- ----------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------
a) Name N4 Pharma plc
----------------------- ----------------------------------------------
b) LEI 213800I841D2RKMFK955
----------------------- ----------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------------
a) Description Options over Ordinary Shares of 0.4p each
of the financial Identification code (ISIN) for N4 Pharma plc
instrument, ordinary shares: GB00BYW8QM32
type of instrument
Identification
code
----------------------- ----------------------------------------------
b) Nature of the Issue of options over ordinary shares of 0.4p
transaction each
----------------------- ----------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) 4.8p exercise
price 717,143
----------
----------------------- ----------------------------------------------
d) Aggregated information n/a
- Aggregated
volume
- Price
----------------------- ----------------------------------------------
e) Date of the 18 May 2020
transaction
----------------------- ----------------------------------------------
f) Place of the Outside a trading venue
transaction
----------------------- ----------------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Luke Cairns
----------------------- ------------------------------------------
2 Reason for the notification
-------------------------------------------------------------------
a) Position/status Non-Executive Director
----------------------- ------------------------------------------
b) Initial notification Initial notification
/Amendment
----------------------- ------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------
a) Name N4 Pharma plc
----------------------- ------------------------------------------
b) LEI 213800I841D2RKMFK955
----------------------- ------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------
a) Description Options over Ordinary Shares of 0.4p
of the financial each
instrument, Identification code (ISIN) for N4
type of instrument Pharma plc ordinary shares: GB00BYW8QM32
Identification
code
----------------------- ------------------------------------------
b) Nature of the Issue of options over ordinary shares
transaction of 0.4p each
----------------------- ------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) 4.8p exercise
price 717,143
----------
----------------------- ------------------------------------------
d) Aggregated information n/a
- Aggregated
volume
- Price
----------------------- ------------------------------------------
e) Date of the 18 May 2020
transaction
----------------------- ------------------------------------------
f) Place of the Outside a trading venue
transaction
----------------------- ------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHAPMATMTTBBMM
(END) Dow Jones Newswires
May 18, 2020 11:29 ET (15:29 GMT)
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
